Literature DB >> 18948125

Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro.

N Crespo-Biel1, A Camins, M Pallàs, A M Canudas.   

Abstract

Lithium reduced striatal neurodegeneration induced in rats by 3-nitropropionic acid inhibiting calpain activation. Lithium prevented an increase in cdk5 activity, as shown by the levels of the co-activator p35. Myocite enhancer factor 2 (MEF2), a downstream substrate for cdk5 with pro-survival activity, showed increased phosphorylation. In primary cultures of neurons treated with 3-NP, lithium also reduced protease activity mediated by calpain, cdk5 activation and cellular death. These observations indicate that lithium has a neuroprotective effect. Lithium treatment also reduced the intracellular increase in calcium induced by 3-NP. The finding that lithium mediates the modulation of the calpain/cdk5 pathway further supports its use in the treatment of neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18948125     DOI: 10.1016/j.neuropharm.2008.09.012

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

1.  Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes.

Authors:  Horacio Maldonado; Eugenio Ramírez; Elias Utreras; María E Pando; Ana M Kettlun; Mario Chiong; Ashok B Kulkarni; Lucía Collados; Javier Puente; Luis Cartier; María A Valenzuela
Journal:  J Neurosci Res       Date:  2011-06-10       Impact factor: 4.164

2.  Phosphorylation of amyloid precursor protein at threonine 668 is essential for its copper-responsive trafficking in SH-SY5Y neuroblastoma cells.

Authors:  Karla M Acevedo; Carlos M Opazo; David Norrish; Leesa M Challis; Qiao-Xin Li; Anthony R White; Ashley I Bush; James Camakaris
Journal:  J Biol Chem       Date:  2014-03-07       Impact factor: 5.157

Review 3.  Neuroprotective action of lithium in disorders of the central nervous system.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-06

Review 4.  Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins.

Authors:  Hua She; Zixu Mao
Journal:  Neurotoxicology       Date:  2011-06-29       Impact factor: 4.294

Review 5.  Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

Authors:  Delphine Meffre; Julien Grenier; Sophie Bernard; Françoise Courtin; Todor Dudev; Ghjuvan'Ghjacumu Shackleford; Mehrnaz Jafarian-Tehrani; Charbel Massaad
Journal:  Cell Mol Life Sci       Date:  2013-06-09       Impact factor: 9.261

Review 6.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

7.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

Review 8.  The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis.

Authors:  Rodrigo Machado-Vieira; Husseini K Manji; Carlos A Zarate
Journal:  Bipolar Disord       Date:  2009-06       Impact factor: 6.744

9.  Lithium: the pharmacodynamic actions of the amazing ion.

Authors:  Kayleigh M Brown; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2013-06

10.  Lithium chloride could aggravate brain injury caused by 3-nitropropionic acid.

Authors:  Aleksandra Milutinović
Journal:  Bosn J Basic Med Sci       Date:  2016-11-10       Impact factor: 3.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.